Article
Study Design and Rationale for the PACE-LUNG Trial: A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients with EGFRm NSCLC with the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib First-Line Treatment.
Clinical lung cancer - 1 Nov 2022
Acker Fabian, Aguinarte Lukas, Althoff Friederike, Heinzen Sophie, Rost Maximilian, Wild Peter, Reiser Lena, Mänz Martin, Meyer Frauke, Stratmann Jan, Sebastian Martin
Abstract excerpt
BACKGROUND: Tyrosine kinase inhibitors (TKI) targeting the epidermal growth factor receptor (EGFR) like the third-generation TKI osimertinib have substantially improved the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring sensitizing EGFR mutations. However, there is a subset of patients that do not benefit from these therapies in terms of response rate or progression-free-survival...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.